Evogene Targets Acute Graft-Versus-Host Disease
Evogene is targeting acute graft-versus-host disease in an AI-driven drug discovery program.
Related stories
Vamos Q3 net profit at 151 million reais
Vamos reported Q3 net profit of 151 million reais, versus the IBES estimate of 134 million reais.
M impact | EQUITY | Oct 29, 2026, 11:18 PM UTC
Glaukos Raises 2026 Net Sales Guidance to $77
Glaukos raised its 2026 net sales guidance to $77; the supplied text provides no unit or further details.
M impact | EQUITY | Oct 29, 2026, 11:17 PM UTC
Pebblebrook Hotel Trust Reports Quarterly Results
Pebblebrook Hotel Trust reported results for the quarter ended September 30.
M impact | EQUITY | Oct 29, 2026, 11:16 PM UTC
Banco del Bajío Publishes Q3 2026 Earnings Call Transcript
Banco del Bajío published a transcript of its Q3 2026 earnings call.
M impact | EQUITY | Oct 29, 2026, 11:16 PM UTC
World Kinect Reports Quarterly Results for Period Ended September 30
M impact | EQUITY | Oct 29, 2026, 11:15 PM UTC
Strattec Security Reports Quarterly Results for Quarter Ended September 30
M impact | EQUITY | Oct 29, 2026, 11:14 PM UTC